Gastroenterology

Projects

Projects per year 2013 2019 2020 2021 2022 2023 2024 2030

• 3 Not started
• 29 Active
• 53 Finished

Projects per year

Search results

• Active

  A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  Roberts, S. (Primary Chief Investigator (PCI))

  3/03/25 → 2/03/27

  Project: Research

• Comparative Analysis of Transabdominal and Transperineal Ultrasound in the Diagnosis and follow-up of Rectal Inflammation and Pelvic Dyssynergia in IBD

  Ardalan, Z. (Primary Chief Investigator (PCI)), Friedman, A. (Associate Investigator (AI)) & Christensen, B. (Associate Investigator (AI))

  Crohn's and Colitis Australia

  1/01/25 → 31/12/26

  Project: Research

• A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, including Hepatocellular Carcinoma

  Roberts, S. (Primary Chief Investigator (PCI))

  25/09/24 → 24/09/26

  Project: Research

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)

  Roberts, S. (Primary Chief Investigator (PCI))

  18/09/24 → 17/09/26

  Project: Research

• A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INI-822 in Healthy Volunteers and Participants with Non-Alcoholic Steatohepatitis (NASH) Or Presumed NASH

  Roberts, S. (Primary Chief Investigator (PCI)) & Mitchell, J. (Project Manager)

  27/08/24 → 26/08/26

  Project: Research

• A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod Alone and in Combinations in Subjects with Chronic Hepatitis B Infection

  Roberts, S. (Primary Chief Investigator (PCI))

  17/08/24 → 17/08/26

  Project: Research

• A PHASE IC, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, IMMUNOGENICITY, AND BIOLOGICAL EFFECTS OF DONQ52 IN CELIAC DISEASE PATIENTS WITH GLUTEN CHALLENGE

  Ket, S. (Primary Chief Investigator (PCI))

  23/07/24 → 20/08/25

  Project: Research

• Centre of Excellence for Cancer Immunotherapy.

  Andrews, M. (Primary Chief Investigator (PCI)), Shackleton, M. (Chief Investigator (CI)), Bucknall, T. (Chief Investigator (CI)), McKimm, A. (Chief Investigator (CI)), Boussioutas, A. (Chief Investigator (CI)), Moore, M. (Chief Investigator (CI)), Kern, J. (Chief Investigator (CI)) & McTier, L. (Chief Investigator (CI))

  1/07/24 → 1/06/26

  Project: Research

• A Long-Term Follow-up Study for Subjects with Chronic Hepatitis B Previously Treated with Imdusiran (AB-729)

  Roberts, S. (Primary Chief Investigator (PCI))

  22/05/24 → 22/05/30

  Project: Research

• A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The “EvolvE” Study)

  Burgell, R. (Primary Chief Investigator (PCI))

  2/04/24 → 2/04/26

  Project: Research

• A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy as well as Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants with Cirrhosis

  Roberts, S. (Primary Chief Investigator (PCI)) & Lewis, P. (Project Manager)

  2/04/24 → 1/04/26

  Project: Research

• A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Safety and efficacy of Efruxifermin in subjects with Non-Cirrhotic Non-alcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  Roberts, S. (Primary Chief Investigator (PCI))

  1/02/24 → 2/02/26

  Project: Research

• An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-negative, and Virally Suppressed

  Roberts, S. (Primary Chief Investigator (PCI)) & Mitchell, J. L. (Project Manager)

  12/01/24 → 11/01/26

  Project: Research

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  Roberts, S. (Primary Chief Investigator (PCI))

  17/11/23 → 17/11/25

  Project: Research

• A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet

  Ket, S. (Primary Chief Investigator (PCI))

  15/11/23 → 15/11/25

  Project: Research

• A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease

  Brown, G. (Primary Chief Investigator (PCI))

  4/09/23 → 4/09/25

  Project: Research

• FAD-UC: Investigating the therapeutic potential of a diet low in sulphite- & carrageenan food additives for ulcerative colitis

  Yao, C. (Primary Chief Investigator (PCI)), Gibson, P. (Chief Investigator (CI)), Biesiekierski, J. (Chief Investigator (CI)), Halmos, E. (Chief Investigator (CI)), Fitzpatrick, J. W. (Chief Investigator (CI)) & Ardalan, Z. (Chief Investigator (CI))

  1/09/23 → 30/11/25

  Project: Research

• An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B

  Roberts, S. (Primary Chief Investigator (PCI)) & McKenzie, J. (Project Manager)

  2/08/23 → 1/08/25

  Project: Research

• Dissecting the role of group 2 innate lymphoid cells in gastric cancer

  Buchert, M. (Primary Chief Investigator (PCI)), Eissman, M. F. (Chief Investigator (CI)), Locksley, R. (Chief Investigator (CI)), Ernst, M. (Associate Investigator (AI)), Li, X. (Associate Investigator (AI)), Boussioutas, A. (Associate Investigator (AI)), Shi, W. (Associate Investigator (AI)), Lee, J. (Associate Investigator (AI)) & Pal, B. (Associate Investigator (AI))

  1/01/23 → 31/12/26

  Project: Research

• ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

  Roberts, S. (Primary Chief Investigator (PCI))

  11/10/22 → 10/10/27

  Project: Research

• AIpathology: Artificial intelligence-enabled cancer diagnosis, type classification and mutation prediction

  Song, J. (Primary Chief Investigator (PCI)), Liò, P. (Chief Investigator (CI)), Imoto, S. (Chief Investigator (CI)), Zhang, D. (Chief Investigator (CI)) & Boussioutas, A. (Chief Investigator (CI))

  1/07/22 → 30/06/25

  Project: Research

• A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS.

  Burgell, R. (Primary Chief Investigator (PCI)), Perananthan, V. (Primary Chief Investigator (PCI)), Burgell, R. (Primary Chief Investigator (PCI)) & Charitra, R. (Project Manager)

  10/06/22 → 31/12/25

  Project: Research

• A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Noncirrhotic Non-alcoholic Steatohepatitis with Fibrosis (PROXYMO-ADVANCE)

  Roberts, S. (Primary Chief Investigator (PCI))

  1/06/22 → 31/08/27

  Project: Research

• TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness.

  Roberts, S. (Primary Chief Investigator (PCI))

  26/02/22 → 1/01/26

  Project: Research

• AGITG TOP GEAR: A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer

  Leong, T. (Primary Chief Investigator (PCI)), Smithers, B. (Chief Investigator (CI)), Lordick, F. (Chief Investigator (CI)), Simes, R. J. (Chief Investigator (CI)), Darling, G. E. (Chief Investigator (CI)), Gebski, V. J. (Chief Investigator (CI)), Boussioutas, A. (Chief Investigator (CI)), Haustermans, K. M. G. (Chief Investigator (CI)), Zalcberg, J. (Chief Investigator (CI)) & Michael, M. Z. (Chief Investigator (CI))

  1/07/21 → 30/06/26

  Project: Research

• A Multicentre, Observational, Phase 4 Study to Evaluate the Safety and Tolerability of Lenvatinib in Patients with Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)

  Roberts, S. (Primary Chief Investigator (PCI)) & Lewis, P. (Project Manager)

  28/05/21 → 31/12/27

  Project: Research

• A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis (EoE)

  Burgell, R. (Primary Chief Investigator (PCI))

  27/04/21 → 31/12/25

  Project: Research

• The role of a low emulsifier diet to treat Crohn's disease

  Halmos, E. (Primary Chief Investigator (PCI))

  1/01/21 → 31/12/25

  Project: Research

• A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.

  Burgell, R. (Primary Chief Investigator (PCI)) & McKenzie, J. (Project Manager)

  26/03/20 → 31/12/25

  Project: Research

• Not started

  Discovery and validation of biomarkers for nonalcoholic steatohepatitis and liver fibrosis

  Watt, M. (Primary Chief Investigator (PCI)), Montgomery, M. K. (Chief Investigator (CI)), Burton, P. (Chief Investigator (CI)), Brown, W. (Chief Investigator (CI)), Roberts, S. (Chief Investigator (CI)), Kemp, W. (Chief Investigator (CI)) & Earnest, A. (Associate Investigator (AI))

  Project: Research

• A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma.

  Roberts, S. (Primary Chief Investigator (PCI)), Lewis, P. (Project Manager), Matos, M. (Chief Investigator (CI)), Zekry, A. (Chief Investigator (CI)) & Haridy, J. (Chief Investigator (CI))

  Project: Research

• A Phase 1/2a - Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects With Chronic Hepatitis B Infection, Including Subjects With Chronic Hepatitis D Infection

  Roberts, S. (Primary Chief Investigator (PCI))

  Project: Research

• Finished

  Consortium for Research expertise in Eating Disorders (CORED)

  Sharp, G. (Primary Chief Investigator (PCI)), Langiu, M. (Chief Investigator (CI)), Ramadas, A. (Chief Investigator (CI)), Yao, C. (Chief Investigator (CI)) & Stafrace, S. (Chief Investigator (CI))

  20/11/23 → 31/12/24

  Project: Research

• NHMRC Equipment Grant - UVITEC Alliance Q9 Advanced imager

  Shackleton, M. (Primary Chief Investigator (PCI)), Boussioutas, A. (Chief Investigator (CI)), Andrews, M. (Chief Investigator (CI)), Naranbhai, V. (Chief Investigator (CI)) & Kong, J. (Chief Investigator (CI))

  1/11/23 → 31/12/24

  Project: Research

• A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)

  Burgell, R. (Primary Chief Investigator (PCI)) & Boussioutas, A. (Chief Investigator (CI))

  4/04/23 → 3/04/25

  Project: Research

• A three-part, double-blind, placebo-controlled, Phase I/Ib study of the safety, tolerability and pharmacokinetics of single and multiple ascending doses of IMU-856 in healthy volunteers and patients with celiac disease.

  Brown, G. (Primary Chief Investigator (PCI))

  20/09/22 → 1/06/24

  Project: Research

• HER2 testing in advanced gastric cancer – understanding and reducing variation in current practice to improve patient survival

  Ioannou, L. (Primary Chief Investigator (PCI)), Zalcberg, J. (Chief Investigator (CI)), Boussioutas, A. (Chief Investigator (CI)), Fox, S. B. (Chief Investigator (CI)), Duong, C. P. (Chief Investigator (CI)), Wong, R. (Chief Investigator (CI)), Chen, R. (Chief Investigator (CI)), Haydon, A. (Chief Investigator (CI)), Graco, M. (Chief Investigator (CI)), Saxon, S. (Associate Investigator (AI)), Ananda, S. (Associate Investigator (AI)), Tagkalidis, P. (Associate Investigator (AI)), Lipton, L. R. (Associate Investigator (AI)), Brown, S. B. (Associate Investigator (AI)), Aga, A. (Associate Investigator (AI)), Hair, C. (Associate Investigator (AI)) & Tawfik, B. (Associate Investigator (AI))

  4/04/22 → 7/04/25

  Project: Research

• The role of a low emulsifier diet in treating Crohn's disease

  Halmos, E. (Supervisor) & Fitzpatrick, J. W. (Primary Chief Investigator (PCI))

  1/02/22 → 24/04/24

  Project: Research

• A Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 in Virologically-Suppressed Chronic Hepatitis B Participants.

  Roberts, S. (Primary Chief Investigator (PCI))

  1/02/22 → 31/12/24

  Project: Research

• Atmo bar : Development of Atmo Cereal bars

  Gibson, P. (Primary Chief Investigator (PCI)), Muir, J. (Chief Investigator (CI)), Yao, C. (Chief Investigator (CI)) & So, D. (Chief Investigator (CI))

  18/10/21 → 17/10/22

  Project: Research

• Efficacy and safety investigation of NNC0194-0499 co-administered with semaglutide in subjects with non-alcoholic steatohepatitis: a dose-ranging, placebo-controlled trial

  Roberts, S. (Primary Chief Investigator (PCI))

  9/09/21 → 31/12/24

  Project: Research

• RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

  Roberts, S. (Primary Chief Investigator (PCI))

  16/07/21 → 31/12/24

  Project: Research

• A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION AND MAINTENANCE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS

  Burgell, R. (Primary Chief Investigator (PCI)), Perananthan, V. (Primary Chief Investigator (PCI)) & Burgell, R. (Primary Chief Investigator (PCI))

  8/07/21 → 31/12/24

  Project: Research

• A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects with Chronic Hepatitis B Virus Infection

  Roberts, S. (Primary Chief Investigator (PCI)), Matthews, G. V. (Chief Investigator (CI)), Sasadeusz, J. (Chief Investigator (CI)), Chen, F. (Chief Investigator (CI)), Valaydon, Z. S. (Chief Investigator (CI)), George, J. (Chief Investigator (CI)), MacQuillan, G. (Chief Investigator (CI)), Thompson, A. J. (Chief Investigator (CI)) & Davison, S. (Chief Investigator (CI))

  12/05/21 → 31/12/22

  Project: Research

• Using dietary therapy to slow the progression of diabetic kidney disease

  Snelson, M. (Primary Chief Investigator (PCI)), Coughlan, M. (Chief Investigator (CI)), Ekinci, E. (Chief Investigator (CI)), Baqar, S. (Chief Investigator (CI)), Muir, J. (Chief Investigator (CI)) & Kellow, N. (Chief Investigator (CI))

  3/05/21 → 31/12/24

  Project: Research

• A Double-Blinded, randomized, Parallel-Group, PHASE 2 Study to investigate the Effect of RO7049665 on the time to relapse following steroid tapering in patients with Autoimmune Hepatitis

  Roberts, S. (Primary Chief Investigator (PCI)) & Jones, A. (Project Manager)

  1/03/21 → 31/12/24

  Project: Research

• The new face of dietary therapy in pouchitis: targeting pathogenic factors from the pouch microbiota

  Gibson, P. (Primary Chief Investigator (PCI)), Yao, C. (Chief Investigator (CI)) & Ardalan, Z. S. M. (Chief Investigator (CI))

  25/01/21 → 31/12/21

  Project: Research

• Randomized, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EP547 in Healthy Subjects with Cholestatic or Uremic Pruritis.

  Roberts, S. (Primary Chief Investigator (PCI)) & Kerr, P. (Chief Investigator (CI))

  1/12/20 → 31/12/22

  Project: Research

• Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double- blind, Placebo-Controlled Study of APT-1011, with an open-label extension, in Adult Subjects with Eosinophilic Esophagitis

  Burgell, R. (Primary Chief Investigator (PCI))

  1/11/20 → 31/12/24

  Project: Research

• A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN 74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC).

  Roberts, S. (Primary Chief Investigator (PCI)), Adams, L. A. (Chief Investigator (CI)), George, J. (Chief Investigator (CI)), Strasser, S. I. (Chief Investigator (CI)), Thompson, A. J. (Chief Investigator (CI)) & Lynch, K. D. (Chief Investigator (CI))

  1/10/20 → 1/11/23

  Project: Research